TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18997670
Drug: Diane(35) Diario
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane(35) Diario (35 microg ethinyl-estradiol plus 2 mg cyproterone acetate)
Study: 15350250
Drug: Dalteparin 2500
Normalized name: dalteparin 2500 intl units/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 2500 U, 2500 U, 5000 U, and 7500 U daily
Study: 7521490
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (0.1 mg/kg in 20 min)
Study: 2589674
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of agitated saline via a peripheral vein
Study: 2589674
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of air via the epidural catheter
Study: 2589674
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (nothing injected)
Study: 2589674
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of air via catheters accidentally inserted in epidural veins
Study: 790358
Drug: Gefarnate, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefarnate, 50 mg four times daily
Study: 790358
Drug: Placebo (dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dummy capsules)
Study: 25307511
Drug: Paricalcitol therapy
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol therapy
Study: 11641676
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microg) every 3 hours
Study: 9408917
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 +/‐ 2.5 mg/day
Study: 9408917
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 +/‐ 2.5 mg/day
Study: 9408917
Drug: Olanzapine 15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 15 +/‐ 2.5 mg/day
Study: 9408917
Drug: Haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 15 +/‐ 5 mg/day
Study: 26141466
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 15.0 g/d
Study: 19317163
Drug: Xiaoyu Zhixue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoyu Zhixue Tablet (XYZXT)
Study: 19317163
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (adrenosin, vitamins C, K and P)
Study: 442223
Drug: Cyclophosphamide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide + Methotrexate + Fluorouracil (CMF) chemotherapy
Study: 29893462
Drug: SOF/VEL/VOX (400/100/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF/VEL/VOX (400/100/100 mg) daily for 12 weeks
Study: 28374512
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (SAL) via two different dry powder inhalers
Study: 28374512
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (SAL)
Study: 9761804
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide (500 microg, 2.5 ml) with albuterol
Study: 19380203
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (TDiclo)
Study: 19380203
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (ODiclo)
Study: 19380203
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac (TDiclo) + Oral diclofenac (ODiclo)
Study: 15286220
Drug: Isotonic amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic amino acid (IAA) solution
Study: 15286220
Drug: 0.25 normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 normal saline (NS) solution
Study: 8237799
Drug: Intravenous 7E3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 7E3 (0.1 mg/kg [n = 5], 0.2 mg/kg [n = 22], 0.15 mg/kg [n = 13], 0.25 mg/kg [n = 20])
Study: 8237799
Drug: Chimeric 7E3
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chimeric 7E3 bolus (up to 0.25 mg/kg) with intravenous continuous infusion of 7E3 (10 micrograms/min for 6 to 24 hours)
Study: 8237799
Drug: Chimeric 7E3
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chimeric 7E3 bolus (up to 0.25 mg/kg) without intravenous continuous infusion of 7E3
Study: 3684122
Drug: Bromocriptine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (50 mg intramuscular injection)
Study: 3684122
Drug: Estandron prolongatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estandron prolongatum (estradiol/testosterone ester combination, single intramuscular dose)
Study: 28688001
Drug: Glecaprevir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir 400 mg + Pibrentasvir 120 mg
Study: 28688001
Drug: Glecaprevir 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir 700 mg + Pibrentasvir 160 mg
Study: 28688001
Drug: Glecaprevir (100-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir (100-1200 mg) + Pibrentasvir (40-200 mg)
Study: 28688001
Drug: Glecaprevir (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir (700 and 1200 mg)
Study: 28688001
Drug: Glecaprevir up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir up to 400 mg + Pibrentasvir
Study: 27149646
Drug: Prediagnostic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prediagnostic aspirin use (1274 women)
Study: 27149646
Drug: Prediagnostic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prediagnostic aspirin use among lymph node-negative tumors
Study: 27149646
Drug: Prediagnostic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prediagnostic aspirin use among lymph node-positive tumors
Study: 22315329
Drug: Rocuronium-sugammadex (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium-sugammadex (1 mg kg(‐1) rocuronium and 16 mg kg(‐1) sugammadex)
Study: 22315329
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg kg(‐1))
Study: 12637609
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa plus low-dose cytarabine
Study: 10700786
Drug: Oral tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenoxicam (40 mg before surgery, 20 mg orally for 8 days)
Study: 10700786
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam (40 mg after surgery, 40 mg i.v. at 24 h after surgery)
Study: 7082779
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 50 mg administered concurrently with propranolol
Study: 7082779
Drug: INDERIDE (40/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: INDERIDE (40/25 mg)
Study: 7082779
Drug: INDERIDE (80/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: INDERIDE (80/25 mg)
Study: 7082779
Drug: Reference formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulations (separate tablets of INDERAL plus HYDRODIURIL)
Study: 31788697
Drug: Aqueous iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aqueous iodine solution (AIS)
Study: 18948412
Drug: CS-0777 (sphingosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-0777 (sphingosine 1-phosphate receptor-1 modulator)
Study: 15561647
Drug: Gabapentin <1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin <1800 mg/d
Study: 15561647
Drug: Gabapentin >=1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin >=1800 mg/d
Study: 25678217
Drug: Ketotifen drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen drops (1 drop every 12 hours) with placebo pills (2 pills daily)
Study: 25678217
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops with ketotifen pills (2 pills daily)
Study: 23812961
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of atomoxetine hydrochloride capsules (40 mg)
Study: 23812961
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of atomoxetine hydrochloride capsules (40 mg)
Study: 21861888
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus bevacizumab (Cape-Bev) - capecitabine 1250 mg/m² bid for 14 days plus bevacizumab 7.5 mg/kg q3w
Study: 21861888
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) - capecitabine 800 mg/m² bid for 14 days, irinotecan 200 mg/m² on day 1, and bevacizumab 7.5 mg/kg q3w
Study: 17920092
Drug: Argemone mexicana
Normalized name: ARGEMONE MEXICANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argemone mexicana decoction, Group A: once daily for 3 days, n=23
Study: 17920092
Drug: Argemone mexicana
Normalized name: ARGEMONE MEXICANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argemone mexicana decoction, Group B: twice daily for 7 days, n=40
Study: 17920092
Drug: Argemone mexicana
Normalized name: ARGEMONE MEXICANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argemone mexicana decoction, Group C: four times daily for the first 4 days followed by twice daily for 3 days, n=17
Study: 8624291
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2, repeated courses every 28 days for 6 cycles)
Study: 1096922
Drug: Experimental drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drugs (various local anaesthetic agents)
Study: 1096922
Drug: Standard local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard local anaesthetic agent
Study: 25554994
Drug: venlafaxine extended-release
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine extended-release
Study: 23185988
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than one line of chemotherapy
Study: 22027749
Drug: Myocet (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocet (60 mg/m intravenously on day 1 every 4 weeks)
Study: 15142030
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g carbohydrate (CHO)/kg body mass carbohydrate beverage (25% solution)
Study: 11517127
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (100 U x kg(‐1) s.c. three times a week for 3 weeks before surgery and i.v. on the day of surgery)
Study: 2629624
Drug: Cereal based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal based oral rehydration solution (made of maize, millet, sorghum, or rice)
Study: 2629624
Drug: World Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: World Health Organisation/United Nations Childrens Fund (WHO/Unicef) recommended oral rehydration solution
Study: 786421
Drug: Disulfiram implants
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram implants
Study: 31236778
Drug: Intraarticular analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular analgesic infusion (IAC) (Group II, n=172 patients)
Study: 23757614
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin C (250 mg/day)
Study: 23757614
Drug: Medium-dose vitamin
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose vitamin C (500 mg/day)
Study: 23757614
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C (1,000 mg/day)
Study: 6354933
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times daily (t.i.d.)
Study: 6354933
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg twice daily (b.i.d.)
Study: 6354933
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg three times daily (t.i.d.)
Study: 6354933
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily (b.i.d.)
Study: 6354933
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times daily (t.i.d.) with chlorthalidone 25 mg daily
Study: 6354933
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg twice daily (b.i.d.) with chlorthalidone 25 mg daily
Study: 31875936
Drug: Baseline UA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline UA levels < 5.0 mg/dL
Study: 31875936
Drug: Baseline UA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline UA levels 5.0-6.0 mg/dL
Study: 31875936
Drug: Baseline UA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline UA levels 6.0-7.0 mg/dL
Study: 31875936
Drug: Baseline UA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline UA levels ≥ 7.0 mg/dL
Study: 30779295
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 mg orally three times daily until 32+0 weeks, birth, or fetal death)
Study: 30779295
Drug: Placebo (visually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (visually matching placebo three times daily until 32+0 weeks, birth, or fetal death)
Study: 26280699
Drug: Ozonated oil
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated oil and α-bisabolol formulation
Study: 26280699
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (vitamin A, vitamin E, talc, and zinc oxide)
Study: 23740278
Drug: High-volume haemofiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume haemofiltration (HVHF) at 70 mL/kg/h
Study: 23740278
Drug: Standard-volume haemofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-volume haemofiltration (SVHF) at 35 mL/kg/h
Study: 21376385
Drug: Eribulin mesilate
Normalized name: Eribulin mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin mesilate (1·4 mg/m² administered intravenously during 2‐5 min on days 1 and 8 of a 21‐day cycle)
Study: 16491283
Drug: hPTH(1-34) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH(1-34) treatment
Study: 11314498
Drug: Helmet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helmet treatment
Study: 11314498
Drug: Nonhelmet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhelmet treatment
Study: 8857040
Drug: Oral bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bile salts (500 mg of sodium deoxycholate 8-hourly for 48 hours preoperatively)
Study: 27768792
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant (4 monthly)
Study: 27768792
Drug: Bevacizumab (monthly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (monthly, pro re nata)
Study: 23036921
Drug: Amoxicillin 3g
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 3g per os
Study: 11996639
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based regimens (e.g., indinavir)
Study: 16392280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without beta‐blockers)
Study: 12356784
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine (3 grams per hour for 10 hours)
Study: 7787408
Drug: Amino acid-enriched
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid-enriched glucose-insulin-potassium infusion (group A)
Study: 375436
Drug: Conventional antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antacid therapy
Study: 31793171
Drug: AZD5718 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (200 mg) coadministered with Rosuvastatin (10 mg)
Study: 31793171
Drug: AZD5718 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (200 mg) as tablets
Study: 31793171
Drug: AZD5718 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (200 mg) tablets after high-fat breakfast
Study: 31793171
Drug: AZD5718 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (200 mg) once-daily
Study: 23324408
Drug: Erythromycin 250
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg orally QID
Study: 23324408
Drug: Neomycin 1
Normalized name: neomycin 1 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin 1 g orally QID
Study: 20663992
Drug: AMG 221
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 221 (3, 30, or 100 mg)
Study: 15584488
Drug: Ibuprofen (Advil)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (Advil)
Study: 15584488
Drug: Acetaminophen (Tylenol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (Tylenol)
Study: 15584488
Drug: Naproxen and
Normalized name: naproxen and misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen and Ibuprofen
Study: 15584488
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three medications
Study: 11710407
Drug: 1200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 ml of distilled water (trial 2)
Study: 11710407
Drug: 1200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 ml of Gatorade (trial 3)
Study: 8000803
Drug: 8% red
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% red cell suspension with diluted commercial sera hyperimmune to Salmonellae and Yersinia, serovars O3 and O9
Study: 3571772
Drug: L-649,923 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-649,923 (1000 mg)
Study: 27739263
Drug: Carica papaya
Normalized name: Carica papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carica papaya leaf extract capsule (500 mg once daily for 5 days)
Study: 27739263
Drug: Routine supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine supportive treatment
Study: 23975179
Drug: Standard-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose cytarabine and anthracycline with risk-adapted remission induction regimen (7+3)
Study: 19035420
Drug: Functional ability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional ability (measured using the Disabilities of the Arm, Shoulder, and Hand questionnaire and the short version of the Sequential Occupational Dexterity Assessment)
Study: 15604591
Drug: Cisplatin monotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin monotherapy (37.5 mg/m² on days 1 + 2 of 4-week schedules)
Study: 15604591
Drug: Cisplatin/Ifosfamide/5-Fluorouracil (PIF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/Ifosfamide/5-Fluorouracil (PIF) regimen (Cisplatin same as above, Ifosfamide 2 g/m², Mesna 0.5 g/m², 5-Fluorouracil 500 mg/m², Folinic acid 30 mg/m² on days 1 + 2, all on 4-week schedules)
Study: 9389673
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (ERCP only if biliary sepsis or obstructive jaundice occurred)
Study: 1914053
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg (n = 31)
Study: 1914053
Drug: propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 80 mg (n = 31)
Study: 6456870
Drug: Buf-Puf epidermabrasion
Normalized name: giant puffball extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buf-Puf epidermabrasion in combination with benzoyl peroxide (BPO)
Study: 6742394
Drug: Midazolam (0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.17 mg/kg)
Study: 6742394
Drug: Diazepam (0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.32 mg/kg)
Study: 30014565
Drug: Active oral
Normalized name: Factive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oral appliance (OA)
Study: 30014565
Drug: Sham oral
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham oral appliance (OA)
Study: 22706631
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (median daily doses of 1,400 IU)
Study: 18580847
Drug: L-5-hydroxytryptophan (5-HTP)
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (5-HTP)
Study: 1978873
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg plus probenecid 500 mg three times a day for 21 days
Study: 1978873
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg twice a day for 21 days
Study: 6989482
Drug: Discontinued therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued therapy after completing three years of continuous complete remission
Study: 26916717
Drug: Preoperative Chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Chemotherapy (ChT)